Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:ARWR NASDAQ:GMTX NASDAQ:IBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$7.39+2.1%$5.44$1.69▼$7.61$658.75M-0.491.21 million shs1.58 million shsARWRArrowhead Pharmaceuticals$18.86-0.1%$15.70$9.57▼$30.41$2.60B0.931.56 million shs1.79 million shsGMTXGemini Therapeutics$55.86+5.5%$49.60$1.16▼$14.10$2.42B-0.12189,291 shs406,536 shsIBRXImmunityBio$2.87+2.9%$2.70$1.83▼$7.48$2.46B0.086.23 million shs5.25 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+3.72%+10.20%+33.09%+107.45%+338.79%ARWRArrowhead Pharmaceuticals+7.64%+11.72%+13.94%+69.94%-25.52%GMTXGemini Therapeutics-0.77%+3.60%+5.90%+36.87%+12.77%IBRXImmunityBio+2.95%+5.68%-18.90%+13.41%-57.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.6137 of 5 stars4.52.00.00.02.92.50.6ARWRArrowhead Pharmaceuticals3.7268 of 5 stars3.42.00.03.41.82.50.0GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIBRXImmunityBio2.2489 of 5 stars3.61.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 3.00Buy$11.7556.04% UpsideARWRArrowhead Pharmaceuticals 2.75Moderate Buy$43.71130.86% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AIBRXImmunityBio 3.20Buy$12.25326.09% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, IBRX, GMTX, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025AMLXAmylyx PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.007/8/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/24/2025AMLXAmylyx PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold6/24/2025AMLXAmylyx PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/24/2025AMLXAmylyx PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.006/17/2025AMLXAmylyx PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/4/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/30/2025AMLXAmylyx PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/28/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M7.68N/AN/A$2.40 per share3.14ARWRArrowhead Pharmaceuticals$3.55M736.60N/AN/A$1.54 per share12.30GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AIBRXImmunityBio$14.74M172.15N/AN/A($0.57) per share-5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$301.74M-$3.11N/AN/AN/AN/A-77.21%-63.84%8/6/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/A20.63N/A-45.33%-12.49%8/6/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AIBRXImmunityBio-$413.56M-$0.58N/AN/AN/A-1,310.30%N/A-121.88%8/11/2025 (Estimated)Latest AMLX, IBRX, GMTX, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A12.0512.05ARWRArrowhead Pharmaceuticals0.315.155.15GMTXGemini TherapeuticsN/A71.4971.49IBRXImmunityBioN/A2.222.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%ARWRArrowhead Pharmaceuticals62.61%GMTXGemini Therapeutics75.42%IBRXImmunityBio8.58%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%ARWRArrowhead Pharmaceuticals4.30%GMTXGemini Therapeutics12.90%IBRXImmunityBio76.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.14 million78.71 millionOptionableARWRArrowhead Pharmaceuticals400138.10 million132.16 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableIBRXImmunityBio590882.62 million204.86 millionOptionableAMLX, IBRX, GMTX, and ARWR HeadlinesRecent News About These CompaniesImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study UpdateJuly 9 at 12:16 PM | tipranks.comUK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituJuly 8 at 8:59 AM | bakersfield.comBImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral CapitalJuly 8 at 8:21 AM | marketbeat.comUK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituJuly 7 at 9:43 PM | businesswire.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What HappenedJuly 7 at 10:39 AM | marketbeat.comBullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA AuthorizationJuly 7 at 10:13 AM | msn.comImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial SuccessJuly 2, 2025 | msn.comImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVAJune 24, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Shares Down 5.1% - Here's WhyJune 23, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.9% - Here's WhyJune 17, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Down - Here's WhyJune 13, 2025 | marketbeat.comImmunityBio: Lymphopenia Opportunity Could Provoke Short SqueezeJune 12, 2025 | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $670,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)June 12, 2025 | marketbeat.comImmunityBio (IBRX) Jumps 18% on Anktiva Access ExpansionJune 10, 2025 | msn.com15 Stocks That Stole The Show Last WeekJune 8, 2025 | insidermonkey.comWhy ImmunityBio, Inc. (IBRX) Skyrocketed TodayJune 4, 2025 | insidermonkey.comImmunityBio receives FDA Expanded Access authorization for Cancer BioShieldJune 3, 2025 | finance.yahoo.comASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic CancerJune 3, 2025 | businesswire.comImmunityBio gets FDA expanded access authorization to treat lymphopenia with AnktivaJune 2, 2025 | msn.comWhy ImmunityBio, Inc. (IBRX) Surged On ThursdayMay 30, 2025 | msn.com10 Firms Drenched in Red TodayMay 23, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMLX, IBRX, GMTX, and ARWR Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$7.39 +0.15 (+2.07%) Closing price 04:00 PM EasternExtended Trading$7.42 +0.03 (+0.41%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Arrowhead Pharmaceuticals NASDAQ:ARWR$18.86 -0.02 (-0.11%) Closing price 04:00 PM EasternExtended Trading$18.86 +0.00 (+0.03%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Gemini Therapeutics NASDAQ:GMTX$55.86 +2.89 (+5.46%) As of 07/9/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.ImmunityBio NASDAQ:IBRX$2.87 +0.08 (+2.87%) Closing price 04:00 PM EasternExtended Trading$2.89 +0.02 (+0.70%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
